Fate Therapeutics wins $15 million grant for lupus-nephritis trial
Fate Therapeutics ($FATE) received a $15 million grant from the California Institute for Regenerative Medicine to support RECLAIM-LN, a Phase 2 study of FT819. The experimental off-the-shelf CAR-T treatment will be evaluated in approximately 53 patients with moderate-to-severe lupus nephritis who have not responded adequately to at least two prior immunosuppressive therapies. The open-label, single-arm trial’s primary assessment is renal response at 26 weeks. Fate describes the study as potentia
0